Carisbamate ( DrugBank: Carisbamate )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
144	Lennox-Gastaut syndrome	3

144. Lennox-Gastaut syndrome

---

Clinical trials : 111 /  Drugs : 72 - (DrugBank : 14) / Drug target genes : 49 - Drug target pathways : 61

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05219617 (ClinicalTrials.gov)	April 28, 2022	6/1/2022	Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension	Seizures;Lennox Gastaut Syndrome	Drug: Carisbamate	SK Life Science, Inc.	NULL	Recruiting	4 Years	55 Years	All	252	Phase 3	United States;Colombia;Israel;Korea, Republic of;Mexico
2	NCT04062981 (ClinicalTrials.gov)	May 3, 2019	30/5/2019	Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome	Phase 1, Open-Label Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome	Lennox Gastaut Syndrome	Drug: Carisbamate	SK Life Science, Inc.	NULL	Active, not recruiting	2 Years	N/A	All	15	Phase 1	United States
3	NCT03731715 (ClinicalTrials.gov)	February 7, 2019	16/10/2018	Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome	Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome	Lennox Gastaut Syndrome	Drug: Carisbamate	SK Life Science, Inc.	NULL	Completed	2 Years	N/A	All	18	Phase 1	United States